(Medical Xpress)—By the time doctors diagnose septic shock, patients often are on a knife's edge. At that point, for every hour that treatment is delayed, a person's risk of death rises an alarming six percent.
Time is of the essence. And CALS animal sciences professor Mark Cook was part of a team that developed a breath biomarker technology capable of detecting septic shock 12 to 48 hours earlier than standard methods. This powerful device, which was patented in 2008 and is making its way through clinical trials, creates an exciting opportunity for new, life-saving medical interventions.
"If you can detect septic shock earlier, then you can begin to explore ways of treating it earlier," says Cook, who already is in the process of developing a promising antibody-based treatment.
Septic shock—or severe sepsis—affects approximately 750,000 people in the United States each year, taking more than 200,000 lives and costing around $17 billion in treatment.
It occurs when a person's immune system, spurred by a bacterial infection or serious physical trauma, launches a massive inflammatory response that can lead to a drop in blood pressure, multiple organ failure and death.
The gastrointestinal tract is believed to be the primary site of this runaway response. Because of that, some scientists call the gut "the motor for sepsis," says Cook. So it's no surprise that Cook looked to the gut for a solution.
With funding from a Robert Draper Technology Innovation Fund grant from the UW–Madison Graduate School, he began working to interfere with the activity of a protein called sPLA2, which is part of the chain of events in the gut that drives septic shock. It is a dual-purpose protein that can act as both an enzyme and a signaling molecule, so it wasn't initially clear which of the protein's roles—enzyme, signaling or both—were involved.
Cook and Jordan Sand, a scientist in Cook's lab, decided to first try blocking the gut protein's ability to signal, guessing that this would calm the immune response. So Sand made a series of antibodies that inhibited sPLA2's signaling function—but not its enzyme function—and then tested them in a mouse model of septic shock.
"We actually made it much worse," says Sand. "We absolutely failed. There's no other way to say it."
Sand went back and made antibodies that blocked only the protein's enzyme function. Those worked. "We had 100 percent survival across the board," says Sand.
If the antibody approach also works in people, this treatment could help patients with septic shock stay alive while they wait for antibiotics and other standard treatments to kick in.
Cook and Sand have filed a patent on the technology. But, Cook notes, "There are still a lot of steps to get this into human medicine."
Explore further: Research identifies potential new treatment for sepsis
Medical Xpress on facebook
Related Stories
Research identifies potential new treatment for sepsis
Nov 14, 2013
Sepsis is the leading cause of in-hospital death and there is no specific treatment for it. Now, research led by Dr. Qingping Feng of Western University (London, Canada) suggests a protein called recombinant human annexin ...
Surviving sepsis with LECT2
Dec 17, 2012
Failure to launch an adequate immune response may be at the root of septic shock, according to a study published in The Journal of Experimental Medicine on December 17th.
Team finds molecule that triggers septic shock
Sep 12, 2013
The body's immune system is set up much like a home security system; it has sensors on the outside of cells that act like motion detectors—floodlights—that click on when there's an intruder rustling in ...
'Obesity paradox': Extra weight linked to better outcomes for septic shock, asthma exacerbation
Oct 22, 2012
Although obesity is linked to a variety of health risks, new research indicates that obese patients may have an advantage over nonobese patients in certain health situations, including septic shock and acute asthma exacerbation.
Use of beta-blocker helps achieve target heart rate level among patients in septic shock
Oct 09, 2013
Andrea Morelli, M.D., of the University of Rome, Italy, and colleagues conducted a study to investigate the effect of the short-acting beta-blocker esmolol on the heart rate of patients with severe septic shock and high risk ...
Recommended for you
Discovering a 'THRIL' that correlates with severity of Kawasaki disease
9 hours ago
Sanford-Burnham Medical Research Institute scientists have discovered a new molecule that forms when certain white blood cells—macrophages—are stimulated in response to pathogens. The molecule, termed ...
Building a better malaria vaccine: Mixing the right cocktail
12 hours ago
A safe and effective malaria vaccine is high on the wish list of most people concerned with global health. Results published on December 26 in PLOS Pathogens suggest how a leading vaccine candidate could ...
Antioxidant drug knocks down multiple sclerosis-like disease in mice
14 hours ago
Researchers at Oregon Health & Science University have discovered that an antioxidant designed more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like ...
Gene therapy for human skin disease produces long-term benefits
17 hours ago
Stem cell-based gene therapy holds promise for the treatment of devastating genetic skin diseases, but the long-term clinical outcomes of this approach have been unclear. In a study online December 26th in the ISSCR's journal ...
Using maths, researchers seek to improve success in transplants
Dec 24, 2013
Given that 10.5% of patients who receive a transplant reject the new organ, researchers at the Center of Research and Advanced Studies of the National Polytechnic Institute (Cinvestav) are working in the ...
Study finds axon regeneration after Schwann cell graft to injured spinal cord
Dec 23, 2013
A study carried out at the University of Miami Miller School of Medicine for "The Miami Project to Cure Paralysis" has found that transplanting self-donated Schwann cells (SCs, the principal ensheathing cells of the nervous ...
User comments
© Medical Xpress 2011-2013, Science X network
(Medical Xpress)—By the time doctors diagnose septic shock, patients often are on a knife's edge. At that point, for every hour that treatment is delayed, a person's risk of death rises an alarming six percent.
Time is of the essence. And CALS animal sciences professor Mark Cook was part of a team that developed a breath biomarker technology capable of detecting septic shock 12 to 48 hours earlier than standard methods. This powerful device, which was patented in 2008 and is making its way through clinical trials, creates an exciting opportunity for new, life-saving medical interventions.
"If you can detect septic shock earlier, then you can begin to explore ways of treating it earlier," says Cook, who already is in the process of developing a promising antibody-based treatment.
Septic shock—or severe sepsis—affects approximately 750,000 people in the United States each year, taking more than 200,000 lives and costing around $17 billion in treatment.
It occurs when a person's immune system, spurred by a bacterial infection or serious physical trauma, launches a massive inflammatory response that can lead to a drop in blood pressure, multiple organ failure and death.
The gastrointestinal tract is believed to be the primary site of this runaway response. Because of that, some scientists call the gut "the motor for sepsis," says Cook. So it's no surprise that Cook looked to the gut for a solution.
With funding from a Robert Draper Technology Innovation Fund grant from the UW–Madison Graduate School, he began working to interfere with the activity of a protein called sPLA2, which is part of the chain of events in the gut that drives septic shock. It is a dual-purpose protein that can act as both an enzyme and a signaling molecule, so it wasn't initially clear which of the protein's roles—enzyme, signaling or both—were involved.
Cook and Jordan Sand, a scientist in Cook's lab, decided to first try blocking the gut protein's ability to signal, guessing that this would calm the immune response. So Sand made a series of antibodies that inhibited sPLA2's signaling function—but not its enzyme function—and then tested them in a mouse model of septic shock.
"We actually made it much worse," says Sand. "We absolutely failed. There's no other way to say it."
Sand went back and made antibodies that blocked only the protein's enzyme function. Those worked. "We had 100 percent survival across the board," says Sand.
If the antibody approach also works in people, this treatment could help patients with septic shock stay alive while they wait for antibiotics and other standard treatments to kick in.
Cook and Sand have filed a patent on the technology. But, Cook notes, "There are still a lot of steps to get this into human medicine."
Explore further: Research identifies potential new treatment for sepsis
Medical Xpress on facebook
Related Stories
Research identifies potential new treatment for sepsis
Nov 14, 2013
Sepsis is the leading cause of in-hospital death and there is no specific treatment for it. Now, research led by Dr. Qingping Feng of Western University (London, Canada) suggests a protein called recombinant human annexin ...
Surviving sepsis with LECT2
Dec 17, 2012
Failure to launch an adequate immune response may be at the root of septic shock, according to a study published in The Journal of Experimental Medicine on December 17th.
Team finds molecule that triggers septic shock
Sep 12, 2013
The body's immune system is set up much like a home security system; it has sensors on the outside of cells that act like motion detectors—floodlights—that click on when there's an intruder rustling in ...
'Obesity paradox': Extra weight linked to better outcomes for septic shock, asthma exacerbation
Oct 22, 2012
Although obesity is linked to a variety of health risks, new research indicates that obese patients may have an advantage over nonobese patients in certain health situations, including septic shock and acute asthma exacerbation.
Use of beta-blocker helps achieve target heart rate level among patients in septic shock
Oct 09, 2013
Andrea Morelli, M.D., of the University of Rome, Italy, and colleagues conducted a study to investigate the effect of the short-acting beta-blocker esmolol on the heart rate of patients with severe septic shock and high risk ...
Recommended for you
Discovering a 'THRIL' that correlates with severity of Kawasaki disease
9 hours ago
Sanford-Burnham Medical Research Institute scientists have discovered a new molecule that forms when certain white blood cells—macrophages—are stimulated in response to pathogens. The molecule, termed ...
Building a better malaria vaccine: Mixing the right cocktail
12 hours ago
A safe and effective malaria vaccine is high on the wish list of most people concerned with global health. Results published on December 26 in PLOS Pathogens suggest how a leading vaccine candidate could ...
Antioxidant drug knocks down multiple sclerosis-like disease in mice
14 hours ago
Researchers at Oregon Health & Science University have discovered that an antioxidant designed more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like ...
Gene therapy for human skin disease produces long-term benefits
17 hours ago
Stem cell-based gene therapy holds promise for the treatment of devastating genetic skin diseases, but the long-term clinical outcomes of this approach have been unclear. In a study online December 26th in the ISSCR's journal ...
Using maths, researchers seek to improve success in transplants
Dec 24, 2013
Given that 10.5% of patients who receive a transplant reject the new organ, researchers at the Center of Research and Advanced Studies of the National Polytechnic Institute (Cinvestav) are working in the ...
Study finds axon regeneration after Schwann cell graft to injured spinal cord
Dec 23, 2013
A study carried out at the University of Miami Miller School of Medicine for "The Miami Project to Cure Paralysis" has found that transplanting self-donated Schwann cells (SCs, the principal ensheathing cells of the nervous ...
User comments
© Medical Xpress 2011-2013, Science X network
0 comments:
Post a Comment